0185: Biweekly Paclitaxel/Carboplatin (Tc) Combination Chemotherapy is Highly Active and Well-Tolerated Treatment in First Line Chemotherapy for Ovarian Cancer

D. Doi; H. Konishi; K. Yoneyama; T. Yahata; K. Fujita; H. Nakayama; S. Kodama; Y. Aoki; H. Asakura; T. Takeshita; K. Tanaka

doi:10.1136/ijgc-00009577-200610001-00185

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

YouTube

Podcasts

Zoom Journal Club
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

ABSTRACT: Poster Session 1: Ovarian – Sunday, October 15, 2006

0185: Biweekly Paclitaxel/Carboplatin (Tc) Combination Chemotherapy is Highly Active and Well-Tolerated Treatment in First Line Chemotherapy for Ovarian Cancer

Main menu

Online download statistics by month:

Online download statistics by month:

Log in using your username and password

Main menu

Log in using your username and password

You are here

Online download statistics by month:

Online download statistics by month:

Read the full text or download the PDF:

Log in using your username and password